Solid Biosciences Inc. to host webinar on SGT-003 gene therapy for Duchenne

Solid Biosciences Inc. to host webinar on SGT-003 gene therapy for Duchenne
Solid Biosciences Inc. Duchenne webinar

Solid Biosciences Inc. announced it will co-host a free community webinar with Defeat Duchenne on Wednesday, May 27, at 1:00 PM ET.

The event will cover SGT-003, Solid Biosciences Inc.'s investigational gene therapy for Duchenne muscular dystrophy, and provide updates on two ongoing Duchenne clinical trials. Attendees will have the opportunity to learn more about the company’s research approach and progress from expert presenters. The initiative reflects growing engagement between biotechs and patient communities seeking advances in rare disease treatments.

Solid Biosciences previously announced advancements in precision gene therapy, presenting new targeting strategies at a major symposium earlier this year. The company has also initiated human trials for its SGT-212 gene therapy, which targets both neuromuscular and cardiac manifestations of Friedreich ataxia in a separate program. These developments come as Solid explores new therapeutic options in rare neuromuscular diseases.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.